Bone marrow purging by photodynamic treatment in children with acute leukemia - Cytoprotective action of Amifostine

Leukemia Research

Volumn 24, Issue 5, 2000, Pages 427-435

  Danilatou, Vassiliki ^a   Lydaki, Evagelia ^a   Dimitriou, Helen ^a   Papazoglou, Theodore ^a   Kalmanti, Maria ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Amifostine; Children; Leukemia; Merocyanine 540; Photodynamic treatment; Purging; Transplantation

Indexed keywords

AMIFOSTINE; MEROCYANINE; METHYLCELLULOSE; TRYPAN BLUE;

ACUTE LEUKEMIA; ARGON LASER; ARTICLE; BONE MARROW PURGING; BURST FORMING UNIT E; CELL KILLING; CELL PROTECTION; CELL STRAIN HL 60; CELL SURVIVAL; CHILD; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; VITAL STAIN;

AMIFOSTINE; BONE MARROW; BONE MARROW PURGING; CELL SURVIVAL; DRUG THERAPY, COMBINATION; HL-60 CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PYRIMIDINONES; RADIATION-PROTECTIVE AGENTS;

EID: 0033994024     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00202-7     Document Type: Article

References (62)

1. Fefer A, Thomas ED, 1990. Marrow transplantation in the treatment of leukemia. In: Henderson ES, Lister TA, editors, Leukemia. Philadelphia, PA: W.B. Saunders, p. 431.
2. Forman S.J., Blume K.G. Allogeneic bone marrow transplantation for acute leukemia. Hematol. Oncol. Clin. North Am. 4(3):1990;517.
3. Zittoun R.A., Mandelli F., Willemze R. et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Engl. J. Med. 332(4):1995;217.
4. Vogelsang G.B., Wagner J.E. Graft-versus-host disease. Hematol. Oncol. Clin. North Am. 4(3):1990;625.
5. Shulman H.M., Hinterberg W. Hepatic veno-occlusive disease- liver toxicity syndrome after bone marrow transplantation. Bone Marrow Trans. 10:1992;197.
6. Zaia J.A. Viral infections associated with bone marrow transplantation. Hem Oncol. Clin. North Am. 4(3):1990;603.
7. Kaizer H., Chow H.S. Autologous bone marrow transplantation (ABMT) in the treatment of cancer. Cancer Inv. 2(3):1984;203.
8. Campana D., Pui C.H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 85(6):1995;1416.
9. Champlin R. Purging: the separation of normal from malignant cells for autologous transplantation. Transfusion. 36:1996;910.
10. Selvaggi K.J., Wilson J.W., Mills L.E. et al. Improved outcome for high risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood. 83(6):1994;1698.
11. Laport J.P., Douay L., Lopez M. et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: A 10-year single institution experience. Blood. 84(11):1994;3810.
12. Udomsakdi C., Eaves C.J., Swolin B. et al. Rapid decline of chronic myeloid leukemic cells in long term culture due to a defect at the leukemic stem cell level. Proc. Natl. Acad. Sci. USA. 89:1992;6192.
13. Sieber F. Elimination of residual tumor cells from autologous bone marrow grafts by dye- mediated photolysis: preclinical data. Photochem. Photobiol. 46(1):1987;71.
14. Sieber F., Stuart R.K., Rowley S.D., Sharkis S.J., Sensenbrenner L.L. Dye- mediated photolysis of normal and neoplastic hematopoietic cells. Leukemia Res. 11(1):1987;43.
15. Atzpodien J., Gulati S.C., Strife A., Clarkson B.D. Photoradiation models for the clinical ex vivo treatment of autologous bone marrow grafts. Blood. 70(2):1987;484.
16. Sieber F., Craig A., Krueger G.L., Smith R.E., Ash R.C. Autotransplantation of bone marrow after extracorporeal purging with Merocyanine 540 and light. Blood. 68(supp 1):1986;292a.
17. Gulliya K.S., Fay J.W., Dowben R.M., Berckholder S., Matthiews J.L. Elimination of leukemic cells by laser photodynamic therapy. Cancer Chem. Pharm. 22:1988;211.
18. Gulliya K.S., Matthiews J.L., Fay J.W., Dowben R.M. Increased survival of normal cells during laser photodynamic therapy: implications for ex vivo autologous bone marrow purging. Life Sci. 42(25):1988;2651.
19. Valinsky J.F., Easton T.G., Reich E. Merocyanine 540 as a fluorescent probe of membranes: selective staining of leukemic and immature hemapoietic cells. Cell. 13:1978;487.
20. O'Brien J.M., Gaffney D.K., Wang T.P., Sieber F. Merocyanine 540- sensitized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity. Blood. 80(1):1992;277.
21. Kalyanaraman B., Feix J.B., Sieber F., Thomas J.P., Girotti A.W. Photodynamic action of Merocyanine 540 on artificial and natural cell membranes: Involvement of singlet molecular oxygen. Proc. Natl. Acad. Sci. USA. 84:1987;2999.
22. Feix J.B., Kalyanaraman B. An electron spin resonance study of Merocyanine 540- mediated type I reactions in liposomes. Photochem. Photobiol. 53(1):1991;39.
23. Henderson B.W., Dougherty T.J. How does photodynamic therapy works? Photochem. Photobiol. 55(1):1992;145.
24. Cappizi R.L., Scheffler B.J., Schein P.S. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer suppl. 72(11):1993;3495.
25. Yuhas J.M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino) ethylphosphorothioic acid. Cancer Res. 40:1980;1519.
26. Calabro- Jones P.M., Aguilera J.A., Ward J.F., Smoluk G.D., Fahey R.C. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res. 48:1988;3634.
27. Fahey R.C. Protection of DNA by thiols. Pharmac. Ther. 39:1988;101.
28. Purdie J.W., Inhaber E.R., Schneider H., Labelle J.L. Interaction of cultured mammalian cells with WR-2721 and its thiol WR-1065: implications for mechanisms of radioprotection. Int. J. Radiat. Biol. 43(5):1983;517.
29. Lydaki E., Dimitriou H., Papazoglou T.h, Bolonaki E., Kalmanti M. Merocyanine 540 mediated photoirradiation of leukemic cells. In vitro inference on cell survival. J. Photochem. Photobiol. B: Biol. 32:1996;27.
30. Lydaki E., Dimitriou H., Papazoglou T.H., Liu W.Q., Kalmanti M. Merocyanine 540 mediated photolysis of normal bone marrow, committed hemopoietic progenitors and neoplastic cells. Implications for bone marrow purging. Leukem. Res. 21(7):1997;641.
31. Atzpodien J., Gulati S.C., Clarkson B.D. Comparison of the cytotoxic effects of Merocyanine 540 on leukemic cells and normal human bone marrow. Cancer Res. 46:1986;4892.
32. Caracciolo D., Clark S., Rovera G. Differential activity of recombinant colony stimulating factors in supporting proliferation of human peripheral blood and bone marrow myeloid progenitors in culture. Br. J. Hematol. 72:1989;306.
33. Gaffney D.K., Sieber F. Merocyanine 540- sensitized photoinactivation of soluble and membrane- bound enzymes in L1210 leukemia cells. Cancer Res. 50:1990;7765.
34. Douay L, Hu C, Giarratana MC, Gorin NC. Comparative effects of Amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin Oncol 1994; 21 (5) Supp 11: 16.
35. List A.F., Heaton R., Glinsmann- Gibson B., Capizzi R.L. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin. Oncol. 23(4):1996;58.
36. Alberts DS. Protection by Amifostine of cyclophosphamide- induced myelosuppresion. Semin Oncol 1999; 26 (2) Supp 7: 37.
37. Wasserman T. Radioprotective effects of Amifostine. Semin Oncol 1999; 26(2) Supp 7: 89.
38. Tannehill SP, Mehta SP. Amifostine and radiation therapy: past, present and future. Semin Oncol 1996; 23(4) Supp 8: 69.
39. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by Amifostine. Semin Oncol 1999; 26(2) Supp 7: 3.
40. Kataoka Y, Perrin J, Hunter N, Milas L, Grdina DJ. Antimutagenic effects of Amifostine: clinical implications. Semin Oncol 1996; 23(4) Supp 8: 53.
41. Milas L., Hunter N., Clifton Stephens L., Peters L.J. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 44:1984;5567.
42. Smoluk G.D., Fahey R.C., Calabro-Jones P.M., Aguilera J.A., Ward J.F. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res. 48:1988;3641.
43. Grdina D.J., Constantinou A., Shigematsu N., Murley J.S. Inhibition of topoisomerase II a activity on CHO K1 cells by 2-[8 aminopropylamino) amino] ethanethiol (WR-1065). Radiat. Res. 138:1994;44.
44. Mitchell J., Judd G.G., Diveley R.R., Choe C.Y., Leyser A. Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33728. Carcinogenesis. 16(12):1995;3063.
45. Liu S.C., Murley J.S., Woloschak G., Grdina D.J. Repression of c-myc gene expression by the thiol and bisulphide forms of the cytoprotector Amifostine. Carcinogenesis. 18(12):1997;2457.
46. Klimecki W, Heaton R, Glinsmann-Gibson B, List AF. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects. Blood 1997; 90(10) Supp 1: 520a (abst).
47. Ramakrishnan N., Catravas G.N. N-(2-mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death. J. Immunol. 148(6):1992;1817.
48. Blazek E.R., Hariharan P.V. Alkaline elution studies of hematoporphyrin- derivative photosensitized DNA damage and repair in chinese hamster ovary cells. Photochem. Photobiol. 40(1):1984;5.
49. Traul D.L., Sieber F. Merocyanine 540- sensitized photoirradiation induces apoptosis in HL-60 leukemia cells. Blood. 80(Supp. 1):1992;143a.
50. Miller A.C., Henderson B.W. The influence of cellular glutathione content on cell survival following photodynamic treatment in vitro. Radiat. Res. 107:1986;83.
51. Dillon J., Kennedy J.C., Pottier R.H., Roberts J.E. In vitro and in vivo protection against phototoxic side effects of photodynamic therapy by radioprotective agents WR-2721 and WR-77913. Photochem. Photobiol. 48(2):1988;235.
52. Gaffney D.K., O'Brien J.M., Sieber F. Modulation by thiols of the Merocyanine 540 -sensitized photolysis of leukemia cells, red cells and herpes simplex virus type 1. Photochem. Photobiol. 53(1):1991;85.
53. Lin F., Geiger P.G., Girotti A.W. Selenoperoxidase mediated cytoprotection against Merocyanine 540- sensitized photoperoxidation and photokilling of leukemia cells. Cancer Res. 52:1992;5282.
54. Lin F., Girroti A.W. Cytoprotection against Merocyanine 540- sensitized photoinactivation of the Na+, K+ adenosine triphosphatase in leukemia cells: glutathione and selenoperoxidase involvement. Photochem. Photobiol. 59(3):1994;320.
55. Valeriote F., Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 42:1982;4330.
56. Taylor C.W., Wang L.M., List A.F., Fernandes D., Paine-Murrieta G.D., Johnson C.S., Capizzi R.L. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur. J. Cancer. 33(10):1997;1693.
57. Treskes M., Boven E., van de Loosdrecht A.A., Wijffels J.F., Cloos J., Peters G.J., Pinedo H.M., van der Vijgh W.J. Effects of the modulating agent WR-2721 on the myelotoxicity and antitumour activity in carboplatin- treated mice. Eur. J. Cancer. 30A(2):1994;183.
58. Douay L., Hu C., Giarratana M.C., Bouchet S., Conlon J., Capizzi R.L., Gorin N.C. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood. 86(7):1995;2849.
59. Meagher R.C., Rothman S.A., Paul P., Koberna P., Willmer C., Baucco P.A. Purging of small-cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated Merocyanine 540 phototreatment. Cancer Res. 49:1989;3637.
60. Issels R.D., Nagele A. Promotion of cystine uptake, increase of glutathione biosynthesis and modulation of glutathione status by S-2-(3-aminopropylamino) ethylphosphorothioic acid (WR-2721) in chinese hamster cells. Cancer Res. 49:1989;2082.
61. Meier T., Issels R.D. Degradation of 2-(3-aminopropylamino) ethanethiol (WR-1065) by Cu- dependent amine oxidases and influence on glutathione status of the chinese hamster ovary cells. Biochem. Pharmacol. 50(4):1995;489.
62. Arrick B.A., Nathan C.F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 44:1984;4224.